The mechanism of Supplemented Liang Xue Xiao Feng Powder(SLXXFP) adjusting blood-heat syndrome psoriasis vulgaris(PV) apoptosis by miR-203-SOCS3-JAK2/STAT3 double-inhibitory pathway

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038591

Enrollment

Unknown

Registered

2020-09-24

Start date

2020-09-23

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Vulgaris

Interventions

experimental group 1:N/A

experimental group 2:Chinese medicine SLXXFP for 8 weeks

Healthy volunteer group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnosis of PV; 2. A diagnosis of blood-heat syndrome; 3. Aged 18 to 70 years; 4. Voluntarily participate in this study; Ability to sign informed consent; Agree to accept the treatment.

Exclusion criteria

Exclusion criteria: 1. With other skin diseases; 2. With other Severe systemic chronic wasting disease; 3. With mental disease; 4. Received systemic glucocorticoids, retinoids or methotrexate medication within a month, or who received topical glucocorticoids within 2 weeks; 5. Scar diathesis.

Design outcomes

Primary

Measure	Time frame
Psoriasis area and severity index score;epidermal thickness;miR-203 mRNA;SOCS3 mRNA;Jak2 mRNA;Bcl-2 mRNA;Bcl-X(L) mRNA;Bax mRNA;Cyt-c mRNA;caspase-3 mRNA;caspase-8 mRNA;caspase-9 mRNA;miR-203 protein;SOCS3 protein;Jak2 protein;Bcl-2 protein;Bcl-X(L) protein;Bax protein;Cyt-c protein;caspase-3 protein;caspase-8 protein;caspase-9 protein;	—

Secondary

Measure	Time frame
Itch score;	—

Countries

China

Contacts

Public ContactHao Pingsheng

Hospital of Chengdu University of Traditional Chinese Medicine

hpswl@126.com+86 13881965024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026